BMC Cancer · 2015 · 74 citations · 27 references
MedicineOncologyUrologyBiomedical ImagingDiagnostic ImagingGenitourinary OncologyBladder CancerBladder ImagingUrologic InterventionsImage-guided ResectionMuscle-invasive Bladder Cancer TherapyNarrow-band ImagingNon-muscle-invasive Bladder Cancer TherapyQuality CriteriaRecurrenceRecurrence Rate AnalysisSurgical Imaging Guidance
BACKGROUND: This study included a network meta-analysis of evidence from randomized controlled trials (RCTs) to assess the therapeutic outcome of transurethral resection (TUR) in patients with non-muscle-invasive bladder cancer assisted by photodynamic diagnosis (PDD) employing 5-aminolaevulinic acid (5-ALA) or hexylaminolevulinate (HAL) or by narrow band imaging (NBI). METHODS: Relevant RCTs were identified from electronic databases. The proceedings of relevant congresses were also searched. Fifteen articles based on RCTs were included in the analysis, and the comparisons were made by qualitative and quantitative syntheses using pairwise and network meta-analyses. RESULTS: Seven of 15 RCTs were at moderate risk of bias for all quality criteria and two studies were classified as having a high risk of bias. The recurrence rate of cancers resected with 5-ALA-based PDD was lower than of those resected using HAL-based PDD (odds ratio (OR) = 0.48, 95 % confidence interval (CI) [0.26-0.95]) but was not significantly different than those resected with NBI (OR = 0.53, 95 % CI [0.26-1.09]). The recurrence rate of cancers resected using HAL-based PDD versus NBI did not significantly differ (OR = 1.11, 95 % CI [0.55-2.1]). All cancers resected using 5-ALA-based PDD, HAL-based PDD, or NBI recurred at a lower rate than those resected using white light cystoscopy (WLC). No difference in progression rate was observed between cancers resected by all methods investigated. CONCLUSIONS: The recurrence rate of some bladder cancers can be decreased by the implementation of either PDD- and NBI-assisted TUR; in real settings, clinicians should consider replacing WLC as the standard imaging technology to guide TUR.
27
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher, A. Liberati, Jennifer Tetzlaff et al. · BMJ · 2009 · 83.3K citations · Full text
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff et al. · PubMed · 2009 · 45.1K citations · Full text
Analysis of data from multiclinic trials
Joseph L. Fleiss · Controlled Clinical Trials · 1986 · 452 citations